Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study

BACKGROUND: Figitumumab is a fully human IgG2 monoclonal antibody targeting the insulin-like growth-factor-1 receptor (IGF-1R). Preclinical data suggest a dependence on insulin-like growth-factor signalling for sarcoma subtypes, including Ewing’s sarcoma, and early reports show antitumour activity o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Olmos, David, Postel-Vinay, Sophie, Molife, L Rhoda, Okuno, Scott H, Schuetze, Scott M, Paccagnella, M Luisa, Batzel, Gretchen N, Yin, Donghua, Pritchard-Jones, Kathryn, Judson, Ian, Worden, Francis P, Gualberto, Antonio, Scurr, Michelle, de Bono, Johann S, Haluska, Paul
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2941877/
https://ncbi.nlm.nih.gov/pubmed/20036194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70354-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars